JPRN-UMIN000053395尚未招募Unknown
ENSURE-GA2 study - ENSURE-GA2 study
CS-Lung0 个研究点目标入组 400 人开始时间: 2024年1月19日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with dimentia (2)Patients with psychiatric disorder (3)Any other patients who are regarded as unsuitable for this study by the investigators
研究者
相似试验
已完成
不适用
The cluster randomized trial for elderly NSCLC patient using geriatric assessments.on-small cell lung cancerJPRN-UMIN000037590EJSG CS-Lung1,021
尚未招募
不适用
GA2LEN SURVEY FOLLOW UP STUDYrhinosinusitis1000170810046304AsthmaNL-OMON32137ondon imperial college: Respiratory Epidemiology & Public Health400
进行中（未招募）
1 期
Randomized study of NGR-hTNF given alone or in combination with doxorubicin in sarcoma patientsocally advanced or metastatic Soft-tissue sarcoma in patients untreated or previously treated with one or more prior systemicregimen.MedDRA version: 14.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018851-88-GBMOLMED69
进行中（未招募）
1 期
GR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS). - NGR016MedDRA version: 9.1Level: HLGTClassification code 10041299ocally advanced or metastatic STS patients untreated or previously treated with one or more prior systemic regimen.EUCTR2010-018851-88-ITMOLMED96
进行中（未招募）
1 期
Estudio de fase 2, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de 10 semanas, para evaluar el grado de alivio sintomático y la seguridad y tolerabilidad de SMP-986 (20 mg, 40 mg, 80 mg y 120 mg) administrado una vez al día durante 8 semanas en pacientes con síndrome de vejiga hiperactivaA 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120 mg) administered once daily for 8 weeks to patients with overactive bladder syndrome - Prueba de concepto de fase 2 de SMP-986 en pacientes con SVHASíndrome de vejiga hiperactiva (SVHA)Overactive Bladder SyndromeMedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-003730-15-ESDainippon Sumitomo Pharma Europe Ltd.710